- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.03. | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | 2.733 | AFX News | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| 11.03. | JPMorgan downgrades Day One Biopharmaceuticals stock rating on Servier acquisition | 4 | Investing.com | ||
| 10.03. | This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday | 2 | Benzinga.com | ||
| 09.03. | Servier acquires International Biotech's Day One Biopharmaceuticals for USD2.5 billion | 3 | Alliance News | ||
| 09.03. | Intnl. Biotechnology - Portfolio company Day One Biopharmaceuticals acquired by Servier | 1 | RNS | ||
| DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 07.03. | Key deals this week: Diana Shipping, Day One BioPharmaceuticals, Hudbay Minerals and more | 24 | Seeking Alpha | ||
| 07.03. | Day One Biopharmaceuticals (DAWN) Climbs to 3-Year High on $2.5-Billion Merger | 1 | Insider Monkey | ||
| 06.03. | Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma | 1 | MedCity News | ||
| 06.03. | Servier Acquiring Day One Biopharmaceuticals For About $2.5 Billion | 1 | pulse2.com | ||
| 06.03. | Servier Acquires Day One Biopharmaceuticals, Expanding Rare Oncology Portfolio | 2 | Contract Pharma | ||
| 06.03. | Servier to build cancer drug pipeline with $2.5B purchase of Day One Biopharmaceuticals | 1 | BioPharma Dive | ||
| 06.03. | TD Cowen downgrades Day One Biopharmaceuticals stock on Servier deal | 3 | Investing.com | ||
| 06.03. | Oppenheimer reiterates Day One Biopharmaceuticals stock rating on Servier deal | 2 | Investing.com | ||
| 06.03. | Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday | 5 | Benzinga.com | ||
| 06.03. | Jones Trading cuts Day One Biopharmaceuticals stock rating on Servier acquisition | 1 | Investing.com | ||
| 06.03. | Jones Trading stuft Day One Biopharmaceuticals nach Servier-Übernahme herab | 1 | Investing.com Deutsch | ||
| 06.03. | Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio | 747 | PR Newswire | Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents... ► Artikel lesen | |
| 06.03. | Day One Biopharma to be acquired by Servier for $2.5B | 9 | Seeking Alpha | ||
| 06.03. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.03. | Day One Biopharmaceuticals, Inc.: Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio | 802 | GlobeNewswire (Europe) | Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total... ► Artikel lesen |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,30 | 0,00 % | BioNTech-Aktie: Vielen Dank, und tschüss! | Die Nachricht über den Gründer-Rückzug bei BioNTech löste zunächst einen regelrechten Ausverkauf aus. Die Aktie des deutschen mRNA-Spezialisten brach im Tief um rund 25% ein. Die folgende kurzfristige... ► Artikel lesen | |
| AMGEN | 298,60 | -1,16 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus | ||
| NOVAVAX | 8,315 | -1,42 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 157,75 | -0,25 % | Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,600 | +0,50 % | Is CRISPR Therapeutics Stock a Buy Now? | ||
| MAINZ BIOMED | 0,526 | -8,52 % | Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors | BERKELEY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber (the "Company" or "Quantum Cyber"), today announced a strategic update in response... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,835 | -5,16 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| INTELLIA THERAPEUTICS | 11,120 | -2,37 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 40,800 | -3,32 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,404 | +0,43 % | BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz | ||
| BIOMARIN PHARMACEUTICAL | 46,690 | -1,71 % | BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO | ||
| SAREPTA THERAPEUTICS | 14,710 | +2,26 % | Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,130 | -6,13 % | Canaccord reiterates Pacific Biosciences stock rating on new chemistry | ||
| EXELIXIS | 35,900 | +0,56 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,818 | -0,37 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen |
DAY ONE BIOPHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 21,390 Euro und damit -0,02 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAY ONE BIOPHARMACEUTICALS INC finden Sie auf Wallstreet Online.